What we're reading, May 23, 2016: Oklahoma governor vetoes bill banning abortion; the FDA approved a new nutrition label highlighting sugar added; and 7 years after death panels, conversations on end-of-life planning are becoming more common.
Oklahoma lawmakers may have passed a controversial bill that would make performing an abortion a felony, but it won’t become law. Governor Mary Fallin vetoed the bill, which was the first of its kind and would effectively ban abortion from the state, according to NPR. Fallin, who has signed 18 bills supporting pro-life values, said the bill was vague and would not withstand a legal challenge. Oklahoma has already made it illegal for anyone who is not a physician to perform an abortion.
The FDA has approved a new nutrition label that breaks out added sugar from the total sugar count. According to The Wall Street Journal, the new panel will list how many grams of sugar was added and what percentage that is of the recommended daily maximum. Food and beverage companies have opposed the new rule because, they claim, there is no difference between added sugars and those that are naturally present. The new rules are aimed at curbing obesity, diabetes, and other health ailments.
Death panels may only be 7 years ago, but conversations on end-of-life planning have changed drastically since then. In the first 6 weeks from the start of Medicare paying for end-of-life planning conversations, 14% of physicians said they had already billed for the new counseling, reported AP.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More